The inhibition of p-AKT, p-MAPK and p-STAT3 by gefitinib and sunitinib as well as sunitinib and sorafenib correlated with the ability of these combinations to effectively inhibit GBM oncosphere growth, although this does not directly demonstrate mechanism. This evidence concerns the gene AKT1 and glioblastoma.